Clinical Guidelines

May 12, 2026

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...

The ASCO Post

May 08, 2026

The Flu Vaccine Face-Off Ends in a Draw

Pragmatic cluster randomized crossover study found no statistically significant difference in laboratory-confirmed influenza during the 2023-2024 season

Conexiant

May 05, 2026

AAP Updates Pediatric Office Emergency Readiness

Guidance addresses office readiness, recommended equipment and medications, and team communication processes for infrequent but high-acuity emergencies.

Conexiant

April 28, 2026

This Week’s Biopharma News: Wave of Antibody Approvals

FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars

The Medicine Maker

April 27, 2026

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

The Medicine Maker

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

April 24, 2026

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...

The ASCO Post

April 24, 2026

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

The ASCO Post

April 23, 2026

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing data sets surrounding T-cell–redirecting therapies in relapsed or refractory multiple...

The ASCO Post

April 23, 2026

Unique Phase I NSCLC Trial Sites Decreasing in United States

The ASCO Post

April 22, 2026

First-Line Zongertinib in Advanced HER2-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

The ASCO Post

LC9 Scores Tied to Better Lung Health in NHANES Analysis

Clinical Guidelines

Unique Phase I NSCLC Trial Sites Decreasing in United States

The Flu Vaccine Face-Off Ends in a Draw

AAP Updates Pediatric Office Emergency Readiness

This Week’s Biopharma News: Wave of Antibody Approvals

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Daily News

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

Unique Phase I NSCLC Trial Sites Decreasing in United States

First-Line Zongertinib in Advanced HER2-Mutant NSCLC

Recommendations

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Surgical Techniques to Remove Subretinal Perfluoro-n-Octane

Trending Now

LC9 Scores Tied to Better Lung Health in NHANES Analysis

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

The New Optometrist

The Pathologist

Clinical Guidelines

Daily News

Recommendations